TJX
51
-3
HAS
37
3
AVGO
35
-7
FE
45
-3
SWKS
36
-10
NFLX
66
-3
ORCL
62
2
INTC
36
-5
CRM
59
-3
BAC
50
-3
RL
70
-3
BMY
35
2
HOG
27
-2
MTCH
37
-2
ALLE
41
-3
NEE
52
-2
AAPL
45
-3
D
37
-3
DE
42
-4
WAT
31
-2
TJX
51
-3
HAS
37
3
AVGO
35
-7
FE
45
-3
SWKS
36
-10
NFLX
66
-3
ORCL
62
2
INTC
36
-5
CRM
59
-3
BAC
50
-3
RL
70
-3
BMY
35
2
HOG
27
-2
MTCH
37
-2
ALLE
41
-3
NEE
52
-2
AAPL
45
-3
D
37
-3
DE
42
-4
WAT
31
-2
Financhill
Back

SELLAS Life Sciences Group 10K Form

Sell
37

SLS
SELLAS Life Sciences Group

Last Price:
1.17
Seasonality Move:
1.69%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SLS News And Ratings

See the #1 stock for the next 7 days that we like better than SLS

SLS Financial Statistics

Sales & Book Value

Annual Sales: $1M
Cash Flow: $-9.68M
Price / Cash Flow: 0
Annual Sales: $0.05
Price / Book: 27.05

Profitability

EPS (TTM): -0.92000
Net Income (TTM): $-34.44M
Gross Margin: $0
Return on Equity: 0%
Return on Assets: 0%

SELLAS Life Sciences Group Earnings Forecast

Key SELLAS Life Sciences Group Financial Ratios

  • The Selling, General & Administrative Expenses for SLS have been equal to 1,258.20% of Gross Profit Margin.
  • The Interest Expense is -0.98% of Operating Income.
  • Per Share Earnings over the last 18 years have been positive in 10 years.

SELLAS Life Sciences Group Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SLS
CUSIP: 81642T
Website: sellaslifesciences.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SLS Technical Analysis vs Fundamental Analysis

Sell
37
SELLAS Life Sciences Group (SLS) is a Sell

Is SELLAS Life Sciences Group a Buy or a Sell?